FDA applies four factors to determine whether a compounded drug is essentially a copy of a commercially available product: Same active ingredient semaglutide or tirzepatide Same route of administration subcutaneous injection Same dosage form injectable solution Same strength matching FDA-approved doses (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, etc.) If your compounded product meets these four criteria, it is essentially a copy of Ozempic, Wegovy, Mounjaro, or Zepbound and it is illegal to compound, prescribe, or dispense
The association with MDD appeared stronger in females than in males, although the formal test for a sex difference was not statistically significant
Results are rolling in throughout this year, and they will determine whether retatrutide reaches pharmacies or joins the long list of promising compounds that never made it
A pooled analysis of these data also revealed that semaglutide significantly slowed the rate of kidney function decline, irrespective of kidney function at baseline [16]
Metabolic optimization: Combining prescription weight loss tools with 24/7 data from a glucose biosensor and Registered Dietitian support helps ensure sustainable results